Incidence of Long COVID-19 at 12-18 Months Following Delta Wave of Coronavirus Disease 2019: Hospital-based Prospective Registry.

Kartik Mittal, Raghubir Singh Khedar, Rajeev Gupta, Shilpa Bharati, Krishna K Sharma, J B Gupta, Alok Mathur
{"title":"Incidence of Long COVID-19 at 12-18 Months Following Delta Wave of Coronavirus Disease 2019: Hospital-based Prospective Registry.","authors":"Kartik Mittal, Raghubir Singh Khedar, Rajeev Gupta, Shilpa Bharati, Krishna K Sharma, J B Gupta, Alok Mathur","doi":"10.59556/japi.72.0609","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Long coronavirus disease 2019 (COVID-19) has emerged as an important consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To identify its incidence 12-18 months following hospitalization in patients with COVID-19, we performed a prospective study.</p><p><strong>Methods: </strong>Virologically confirmed successive patients with moderate-to-severe COVID-19, hospitalized during the delta wave in India, were recruited. Data on clinical features, investigations, and outcomes were obtained. Long COVID-19 was diagnosed using the European quality of life questionnaire (EQ-5D) and Birmingham symptom burden questionnaire (SBQ) at 12-18-month follow-up.</p><p><strong>Results: </strong>During the study period (January-July 2021), we evaluated 8,680 suspected COVID-19 patients, of whom 1,641 were confirmed virologically and 388 were hospitalized. Men accounted for 64.4%, individuals aged >60 years for 41.5%, hypertension for 42.8%, diabetes for 38.4%, and cardiovascular disease for 17.3%. At admission, there was a high prevalence of cough (71.1%), fever (86.6%), and oxygen requirement (38.6%). Proning was deployed in 89.2% of cases, nasal cannula in 36.3%, nonrebreather masks in 15.7%, noninvasive ventilation in 14.4%, and invasive ventilation in 16.2%. In-hospital deaths totaled 75 (19.3%), with 310 discharged for home care and eligible for follow-up. At a median follow-up of 15 months, 9 patients had died, 40 were lost to follow-up, and 264 were evaluated. The incidence of Long COVID-19 was 45 [17.0%, 95% confidence of interval (CI) 12.6-21.9%]. The median EQ-5D score was 5.0, with >5 observed in only 11 patients (0.6%). Using the SBQ, new-onset dyspnea on exertion was noted in 13 (4.9%), rest dyspnea in 7 (2.6%), fatigue in 31 (11.7%), feverishness in 18 (6.8%), and low energy in 16 (6.1%). Long COVID-19 was significantly more prevalent in women and older individuals. In Long COVID-19 compared to controls, the mean duration of oxygen requirement (5.46 ± 9.8 vs 2.46 ± 4.5 days, <i>p</i> = 0.002), use of nonrebreather masks (17.8 vs 7.3%, <i>p</i> = 0.026), noninvasive ventilation (11.1 vs 3.2%, <i>p</i> = 0.020), and duration of intensive care unit (ICU) stay (13.5, 8.7-17.3 vs 8.0, 5.0-11.0 days, <i>p</i> = 0.028) were significantly higher.</p><p><strong>Conclusion: </strong>The incidence of Long COVID-19 at 12-18 months follow-up is 17.0%. It is significantly higher in women, older age groups, and patients requiring longer oxygenation, nonrebreather oxygen masks, noninvasive respiratory support, and extended stays in the ICU.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"72 10","pages":"13-18"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of the Association of Physicians of India","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59556/japi.72.0609","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Long coronavirus disease 2019 (COVID-19) has emerged as an important consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To identify its incidence 12-18 months following hospitalization in patients with COVID-19, we performed a prospective study.

Methods: Virologically confirmed successive patients with moderate-to-severe COVID-19, hospitalized during the delta wave in India, were recruited. Data on clinical features, investigations, and outcomes were obtained. Long COVID-19 was diagnosed using the European quality of life questionnaire (EQ-5D) and Birmingham symptom burden questionnaire (SBQ) at 12-18-month follow-up.

Results: During the study period (January-July 2021), we evaluated 8,680 suspected COVID-19 patients, of whom 1,641 were confirmed virologically and 388 were hospitalized. Men accounted for 64.4%, individuals aged >60 years for 41.5%, hypertension for 42.8%, diabetes for 38.4%, and cardiovascular disease for 17.3%. At admission, there was a high prevalence of cough (71.1%), fever (86.6%), and oxygen requirement (38.6%). Proning was deployed in 89.2% of cases, nasal cannula in 36.3%, nonrebreather masks in 15.7%, noninvasive ventilation in 14.4%, and invasive ventilation in 16.2%. In-hospital deaths totaled 75 (19.3%), with 310 discharged for home care and eligible for follow-up. At a median follow-up of 15 months, 9 patients had died, 40 were lost to follow-up, and 264 were evaluated. The incidence of Long COVID-19 was 45 [17.0%, 95% confidence of interval (CI) 12.6-21.9%]. The median EQ-5D score was 5.0, with >5 observed in only 11 patients (0.6%). Using the SBQ, new-onset dyspnea on exertion was noted in 13 (4.9%), rest dyspnea in 7 (2.6%), fatigue in 31 (11.7%), feverishness in 18 (6.8%), and low energy in 16 (6.1%). Long COVID-19 was significantly more prevalent in women and older individuals. In Long COVID-19 compared to controls, the mean duration of oxygen requirement (5.46 ± 9.8 vs 2.46 ± 4.5 days, p = 0.002), use of nonrebreather masks (17.8 vs 7.3%, p = 0.026), noninvasive ventilation (11.1 vs 3.2%, p = 0.020), and duration of intensive care unit (ICU) stay (13.5, 8.7-17.3 vs 8.0, 5.0-11.0 days, p = 0.028) were significantly higher.

Conclusion: The incidence of Long COVID-19 at 12-18 months follow-up is 17.0%. It is significantly higher in women, older age groups, and patients requiring longer oxygenation, nonrebreather oxygen masks, noninvasive respiratory support, and extended stays in the ICU.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2019年冠状病毒疾病三角洲浪潮后12-18个月的长COVID-19发病率:基于医院的前瞻性登记。
背景和目的:2019年长冠状病毒病(COVID-19)已成为严重急性呼吸系统综合征冠状病毒2(SARS-CoV-2)的一个重要后果。为了确定 COVID-19 患者住院后 12-18 个月的发病率,我们进行了一项前瞻性研究:方法:我们招募了在印度三角洲浪潮期间住院的病毒学确诊的中重度 COVID-19 连续患者。获得了临床特征、检查和结果数据。在 12-18 个月的随访中,使用欧洲生活质量问卷(EQ-5D)和伯明翰症状负担问卷(SBQ)对长 COVID-19 进行诊断:在研究期间(2021 年 1 月至 7 月),我们对 8680 名疑似 COVID-19 患者进行了评估,其中 1641 人经病毒学证实,388 人住院治疗。男性占 64.4%,年龄大于 60 岁的占 41.5%,高血压占 42.8%,糖尿病占 38.4%,心血管疾病占 17.3%。入院时,咳嗽(71.1%)、发烧(86.6%)和需氧(38.6%)的发病率很高。89.2%的病例使用了卧床,36.3%的病例使用了鼻插管,15.7%的病例使用了非呼吸面罩,14.4%的病例使用了无创通气,16.2%的病例使用了有创通气。院内死亡总计 75 例(19.3%),其中 310 例出院在家接受护理,符合随访条件。中位随访时间为 15 个月,9 名患者死亡,40 名患者失去随访机会,264 名患者接受了评估。Long COVID-19 的发生率为 45 [17.0%, 95% 置信区间 (CI) 12.6-21.9%]。EQ-5D 评分的中位数为 5.0,只有 11 名患者(0.6%)的 EQ-5D 评分大于 5。使用 SBQ,13 名患者(4.9%)出现新发的劳力性呼吸困难,7 名患者(2.6%)出现休息性呼吸困难,31 名患者(11.7%)出现疲劳,18 名患者(6.8%)出现发热,16 名患者(6.1%)出现精力不足。长COVID-19在女性和老年人中的发病率明显更高。与对照组相比,长 COVID-19 的平均需氧时间(5.46 ± 9.8 对 2.46 ± 4.5 天,p = 0.002)、使用非呼吸面罩(17.8 对 7.3%,p = 0.026)、无创通气(11.1 vs 3.2%,p = 0.020)和重症监护室(ICU)住院时间(13.5,8.7-17.3 vs 8.0,5.0-11.0 天,p = 0.028)均显著增加:结论:在12-18个月的随访中,长COVID-19的发生率为17.0%。结论:在 12-18 个月的随访中,长 COVID-19 的发生率为 17.0%,女性、年龄较大的群体以及需要更长时间吸氧、使用非呼吸氧气面罩、无创呼吸支持和延长重症监护室住院时间的患者的发生率明显更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
509
期刊最新文献
Bilateral Thoracic Herpes Zoster in a 62-year-old Immunocompetent Woman. Comparison of Basal Core Promoter Region Mutation and Precore Mutation among Monoinfected Hepatitis B Virus and Coinfected Hepatitis B Virus with Human Immunodeficiency Virus Patients. Conventional Synthetic Disease-modifying Drugs Remain the Mainstay of Therapy for Rheumatoid Arthritis in India. Current Update on Promising New Anti-Alzheimer's Drugs in Different Phases of Clinical Development: Where Exactly Are We Lacking? Evaluation of Prescription Pattern of Antihypertensives and Its Compliance with Joint National Committee 8 Guidelines in Hospital Setting.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1